$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Pharmacokinetics and Bioequivalence of Haloperidol Tablet by Liquid Chromatographic Mass Spectrometry with Electrospray Ionization

Abstract

The purpose of this study is to investigate the bioequivalence of two haloperidol 5 mg tablets, Myung In haloperidol (Myung In Pharm. Co., Ltd., test drug) and $Peridol^{R}$(Whanin Pharm. Co., Ltd., reference drug), and also to estimate the pharmacokinetic parameters of haloperidol in Korean volunteers. The bioavailability and pharmacokinetics of haloperidol tablets were examined on 24 healthy volunteers who received a single oral dose of each preparation in the fasting state in a randomized balanced 2 way crossover design. After an oral dosing, blood samples were collected for a period of 60 h. Plasma concentrations of haloperidol were determined using a liquid chromatographic electrospray mass spectrometric (LC-MS) method. The pharmacokinetic parameters were calculated with noncompartmental pharmacokinetic analysis. The geometric means of $AUC_{0-60h} and C_{max}$ between test and reference formulations were $17.21\pm8.26 ng\cdot/mL vs 17.31\pm13.24 ng\cdot/mL and 0.87\pm0.74 ng/mL vs 0.85\pm0.62 ng/mL$. respectively. The $90\%$ confidence intervals of mean difference of logarithmic transformed $AUC_{0-60h} and C_{max} were log0.9677{\sim}log1.1201 and log0.8208{\sim}log1.1981$, respectively. It shows that the bioavailability of test drug is equivalent with that of reference drug. The geometric means of other pharmacokinetic parameters ($AUC_{inf}. t_{1/2}, V_{d}/F, and CL/F$) between test drug and reference drug were $21.75\pm8.50 ng{\cdot}h/mL vs 21.77\pm15.63 ng{\cdot}h/mL, 29.87\pm8.25 h vs 29.60\pm7.56 h, 11.51\pm5.45 L vs 12.90\pm6.12 L and 0.26\pm0.09 L/h vs 0.31\pm0.17 L/h$, respectively. These observations indicate that the two formulation for haloperidol was bioequivalent and, thus, may be clinically interchangeable.

참고문헌 (11)

  1. Forsman, A. and Ohman, R., Studies on serum protein binding of haloperidol. Curr. Ther. Res. Clin. Exp., 21, 245-255 (1977) 
  2. Lacy C., Drug Information Handbook, 8th ed. APHA. 988-989 (2000-2001) 
  3. Hoja, H., Marquet, P., Verneuil, B., Lotfi, H., Dupuy, J. L., Penicaut, B., and Lachatre, G., Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization. J. Chromatography B, 688, 275-280 (1997) 
  4. Ser, F. S., Veljkovie, M., Lazovie, M., and Tomie-Pavlovie, I., Delusions of parasitosis-combined therapy with clomipramine and haloperidol. Journal of the European Academy of Dermatology and Venereology, 9, S237 (1997) 
  5. Arinobu, T., Hattori, H., Iwai, M., Ishii, A., Kumazawa, T., Suzuki, O., and Seno, H., Liquid chromatographic–mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. J. Chromatography B, 776, 107-113(776) (2002) 
  6. Altamura, A. C., Relapse prevention with neuroleptics in schizophrenia: The role of their bioavailability and pharmacodynamic profile. European Neuropsychopharmacology, 6, S4 (1996) 
  7. Grohmann, R., Koch, R., and Schmidt, L. G., Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl., 29, 71-82 (1990) 
  8. Someya, T., Shibasaki, M., Noguchi, T., Takahashi, S., and Inaba, T., Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J. Clin. Psychopharmacol, 12, 169-174 (1992) 
  9. Walter, S., Bauer, S., Roots, I., and Brockmoller, J., Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J. Chromatography B, 720, 211-237 (1998) 
  10. Casey, D. E. and Keepers, G. A., Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol, 5, 74-93 (1998) 
  11. McEvoy, G. K., AHFS Drug Information, 2128-2129 (2002) 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일